Hikma Pharmaceuticals

Strong Generics-led finish to 2023

22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."

PDF page sample
Pages
46
Language
English
Published on
22/02/24
Download
You may also be interested by these reports :
26/07/24
The Q2 results came in ahead of expectations, driven by a strong showing across most target areas. As we had indicated the possibility earlier, the ...
26/07/24
The Q2 results beat the market’s expectations, driven by the robust momentum for Dupixent, the healthy trajectory for new launches, and strong growth ...
26/07/24
The outlook has improved, though challenges remain. The company initially lost credibility after announcing a weak 2024 outlook back in the autumn of ...
25/07/24
The Q2 results came in ahead of expectations, with healthy growth witnessed across the targeted areas. Consequently, the management revised its ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO